Results 21 to 30 of about 26,125 (257)

Bispecific antibody target pair discovery by high-throughput phenotypic screening using in vitro combinatorial Fab libraries

mAbs, 2021
Bispecific antibodies can uniquely influence cellular responses, but selecting target combinations for optimal functional activity remains challenging.
Pallavi Bhatta, Kevin D. Whale, Amy K. Sawtell, Clare L. Thompson, Stephen E. Rapecki, David A. Cook, Breda M. Twomey, Milena Mennecozzi, Laura E. Starkie, Emily M. C. Barry, Shirley J. Peters, Ahmad M. Kamal, Helene M. Finney   +12 more
doaj   +1 more source

Engineering SARS-CoV-2 specific cocktail antibodies into a bispecific format improves neutralizing potency and breadth

Nature Communications, 2022
Bispecific antibodies can have advantages compared to antibody cocktails. Here, the authors engineer and characterize two different approaches for generating bispecific SARS-CoV-2 specific antibodies and find that only one design increases antigen ...
Zhiqiang Ku, Xuping Xie, Jianqing Lin, Peng Gao, Bin Wu, Abbas El Sahili, Hang Su, Yang Liu, Xiaohua Ye, Eddie Yongjun Tan, Xin Li, Xuejun Fan, Boon Chong Goh, Wei Xiong, Hannah Boyd, Antonio E. Muruato, Hui Deng, Hongjie Xia, Jing Zou, Birte K. Kalveram, Vineet D. Menachery, Ningyan Zhang, Julien Lescar, Pei-Yong Shi, Zhiqiang An   +24 more
doaj   +1 more source

Function and mechanism of bispecific antibodies targeting SARS-CoV-2

Cell Insight
As the dynamic evolution of SARS-CoV-2 led to reduced efficacy in monoclonal neutralizing antibodies and emergence of immune escape, the role of bispecific antibodies becomes crucial in bolstering antiviral activity and suppressing immune evasion.
Zhaohui Li, Zengyuan Zhang, Steven T. Rosen, Mingye Feng   +3 more
doaj   +1 more source

Bp-Bs, a Novel T-cell Engaging Bispecific Antibody with Biparatopic Her2 Binding, Has Potent Anti-tumor Activities

Molecular Therapy: Oncolytics, 2019
Patients with Human epidermal growth factor receptor type 2 (Her2) overexpression are associated with aggressive tumor growth and poor clinical outcomes.
Jiayu Liu, Xiaoqiong Wu, Limin Lin, Haitao Pan, Yanlan Wang, Yumei Li, Yining Zhao, Zhong Wang   +7 more
doaj   +1 more source

Current landscape and future directions of bispecific antibodies in cancer immunotherapy

Frontiers in Immunology, 2022
Recent advances in cancer immunotherapy using monoclonal antibodies have dramatically revolutionized the therapeutic strategy against advanced malignancies, inspiring the exploration of various types of therapeutic antibodies.
Jing Wei, Yueyao Yang, Gang Wang, Ming Liu   +3 more
doaj   +1 more source

Bispecific antibodies in cancer immunotherapy [PDF]

Current Opinion in Biotechnology, 2020
Among antibody-based cancer therapies, bispecific antibodies (biAbs) have gained momentum in preclinical and clinical investigations following the regulatory approvals of the trailblazing T-cell engaging biAb (T-biAb) blinatumomab. Discussed herein are recent strategies that aim at boosting the potency and mitigating the toxicity of T-biAbs, broadening
openaire   +2 more sources

Effective cancer immunotherapy combining mRNA-encoded bispecific antibodies that induce polyclonal T cell engagement and PD-L1-dependent 4-1BB costimulation

Frontiers in Immunology
BackgroundImmune checkpoint inhibitors have revolutionized cancer therapy, but many patients fail to respond or develop resistance, often due to reduced T cell activity.
Oana Hangiu, Oana Hangiu, Oana Hangiu, Rocío Navarro, Susana Frago, Laura Rubio-Pérez, Laura Rubio-Pérez, Laura Rubio-Pérez, Antonio Tapia-Galisteo, Antonio Tapia-Galisteo, Antonio Tapia-Galisteo, Laura Díez-Alonso, Laura Díez-Alonso, Laura Díez-Alonso, Marina Gómez-Rosel, Marina Gómez-Rosel, Marina Gómez-Rosel, Noelia Silva-Pilipich, Noelia Silva-Pilipich, Lucía Vanrell, Cristian Smerdou, Cristian Smerdou, Kenneth A. Howard, Laura Sanz, Luis Álvarez-Vallina, Luis Álvarez-Vallina, Luis Álvarez-Vallina, Marta Compte   +27 more
doaj   +1 more source

Bispecific antibodies in cancer immunotherapy [PDF]

Human Vaccines & Immunotherapeutics, 2016
Cancer immunotherapy has recently generated much excitement after the continuing success of the immunomodulating anti-CTLA-4 and anti-PD-1 antibodies against various types of cancers. Aside from these immunomodulating antibodies, bispecific antibodies, chimeric antigen receptor T cells, and other technologies are being actively studied.
Siqi, Chen, Jing, Li, Qing, Li, Zhong, Wang   +3 more
openaire   +2 more sources

Format chain exchange (FORCE) for high-throughput generation of bispecific antibodies in combinatorial binder-format matrices

Nature Communications, 2020
Bispecific antibodies have been generated in many different formats and it is becoming clear that rational design alone cannot create optimal functionalities.
Stefan Dengl, Klaus Mayer, Felix Bormann, Harald Duerr, Eike Hoffmann, Bianca Nussbaum, Michael Tischler, Martina Wagner, Andreas Kuglstatter, Lea Leibrock, Can Buldun, Guy Georges, Ulrich Brinkmann   +12 more
doaj   +1 more source

CAR T‐Cell Therapy in Neurology: A Scoping Review of Neuro‐Oncology, Autoimmune Diseases & Neurotoxicity

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Chimeric antigen receptor (CAR) T‐cell therapy has been investigated in neurological diseases, encompassing both central nervous system malignancies and autoimmune disorders, thereby extending its application beyond hematological cancers.
Omar Alqaisi, Mohammed Dibas, Patricia Tai, Ala Dibas, Osama Souied, Suhair Al‐Ghabeesh   +5 more
wiley   +1 more source